Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Kezar Life Sciences (KZR) Receivables - Other (2023 - 2025)

Kezar Life Sciences' Receivables - Other history spans 3 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Receivables - Other rose 248.2% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, up 248.2%, while the annual FY2024 figure was $424000.0, 38.99% down from the prior year.
  • Receivables - Other for Q3 2025 was $1.7 million at Kezar Life Sciences, up from $254000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $2.4 million in Q1 2024 and bottomed at $254000.0 in Q2 2025.
  • The 3-year median for Receivables - Other is $1.0 million (2023), against an average of $1.1 million.
  • The largest YoY upside for Receivables - Other was 248.2% in 2025 against a maximum downside of 80.64% in 2025.
  • A 3-year view of Receivables - Other shows it stood at $695000.0 in 2023, then plummeted by 38.99% to $424000.0 in 2024, then soared by 310.61% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Receivables - Other are $1.7 million (Q3 2025), $254000.0 (Q2 2025), and $1.7 million (Q1 2025).